Prostate Cancer
Chapters
1 Information about this Guideline
2 Introduction
3 Epidemiology, risk factors, prevention, and nutrition
4 Early detection
5 Diagnosis and staging
6 Treatment of non-metastatic prostate carcinoma
7 Diagnosis and treatment of recurrent or metastatic prostate carcinoma
8 Rehabilitation
9 Aftercare
10 Psychosocial aspects and quality of life
11 Quality indicators
12 Research questions
13 Attachments
14 Abbildungsverzeichnis
15 Tabellenverzeichnis
16 Literaturverzeichnis
Search guideline
Recommendations
PDF
More
Cover
Recommendations
Settings
All guidelines
Chapters
1 Information about this Guideline
2 Introduction
3 Epidemiology, risk factors, prevention, and nutrition
4 Early detection
5 Diagnosis and staging
6 Treatment of non-metastatic prostate carcinoma
7 Diagnosis and treatment of recurrent or metastatic prostate carcinoma
8 Rehabilitation
9 Aftercare
10 Psychosocial aspects and quality of life
11 Quality indicators
12 Research questions
13 Attachments
14 Abbildungsverzeichnis
15 Tabellenverzeichnis
16 Literaturverzeichnis
Search guideline
Cover
Recommendations
Settings
All guidelines
15
Tabellenverzeichnis
1
Table 1
Beteiligte Fachgesellschaften und Organisationen
Open table
2
Table 2
Overview of absolute data on benefits and harms of PSA-assisted screening according to Schröder et al. 2014
Open table
3
Table 3
Overview of risks identified in Lilja et al. 2011 and control intervals suggested by the authors of the study
Open table
4
Table 4
Detection rate ratio (Drost et al. 2019)
Open table
5
Table 5
Diagnostic precision in the detection of metastases (primary endpoint).
Open table
6
Table 6
Weight of concomitant diseases contributing to the Charlson score (Charlson et al. 1987). The Charlson score is calculated by totaling a patient's scores
Open table
7
Table 7
American Society of Anesthesiologists (ASA) health status classification (American Society of Anesthesiologists 2013)
Open table
8
Table 8
Studies of prostate cancer under Active Surveillance with at least 5 years of median follow-up and at least 90 patients.
Open table
9
Table 9
Morbidity and mortality after radical prostatectomy
Open table
10
Table 10
Results of the three large RCTs on hypofractionation
Open table
11
Table 11
LDR brachytherapy in noncomparative cohort studies
Open table
12
Table 12
Cohort studies comparing LDR brachytherapy
Open table
13
Table 13
Oncological endpoints of large cohort studies (n > 300) on HIFU in localized prostate cancer
Open table
14
Table 14
Results (follow-up > 7 years) of collectives with cT3-cT4 treated with RPE
Open table
15
Table 15
TNM classification (7th edition) for stages T3 and T4 (source: www.cancerstaging.org)
Open table
16
Table 16
Results from the RCT TITAN on combination therapy with apalutamide, median observation time 22.7 months [Chi et al. 2019; Agarwal et al. 2019]
Open table
17
Table 17
Results from the ARCHES RCTs on combination therapy with enzalutamide (median observation time 14.4 months) [Armstrong et al. 2019]
Open table
18
Table 18
Results of RCT on combination therapy with abiraterone [Fizazi et al. 2017/2019; James et al. 2017]
Open table
19
Table 19
Results of the RCT on combined hormone chemotherapy
Open table
20
Table 20
Typical and common side effects of hormone ablative therapy and possibilities of prophylaxis and treatment to be communicated to the patient (based on Heidenreich 2007)
Open table
21
Table 21
Prophylaxis and treatment of common side effects of chemotherapy in prostate cancer
Open table
22
Table 22
WHO pain management scheme
Open table
23
Table 23
Key questions and author groups
Open table
24
Table 24
Changes in the recommendations after update 6 of 2021
Open table
25
Table 25
Comparative overview of the side effect profile of prostate carcinoma treatments
Open table
← Abbildungsverzeichnis
Literaturverzeichnis →
Open interactive reader